Peng Jun Xu

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

ABSTRACT Chimeric antigen receptor (CAR)‐engineered cell therapies are being extended from hematological malignancies to autoimmune, inflammatory, and fibrotic diseases, although the maturity of evidence differs markedly among platforms and indications. Early clinical evidence fr...